Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00365183 · ClinicalTrials.gov registry record · Phase 2
Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Pharmacyclics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
NCT00365183: Clinical Trial Phase 2 study, sponsored by Pharmacyclics.
NCT00365183 is a Phase 2 study that was terminated before completion, run by Pharmacyclics. The registered enrollment target is 74 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00365183, a Phase 2 study, was terminated before completion, sponsored by Pharmacyclics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
Study Summary
The goals of this study are: * to determine if the combination of two drugs, motexafin gadolinium and pemetrexed, may be an effective treatment for patients with non-small cell lung cancer (NSCLC) who have had one previous chemotherapy regimen that included a platinum containing drug such as cisplatin or carboplatin. * to assess response to treatment in patients with NSCLC six months after beginning study treatment.
Primary Outcome
proportion of patients who are still alive and who have not progressed clinically or radiographically 6 months after receiving their first dose of MGd.
Interventions
- DRUG Motexafin gadolinium and pemetrexed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2006-06 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
Why NCT00365183 stopped before completion
NCT00365183 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower).
The record links to 0 conditions, and to 1 intervention - of which Motexafin gadolinium and pemetrexed is the first listed.
NCT00365183 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00365183 about?
NCT00365183 is a clinical study titled "Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer". The goals of this study are: * to determine if the combination of two drugs, motexafin gadolinium and pemetrexed, may be an effective treatment for patients with non-small cell lung cancer (NSCLC) who have had one previous chemotherapy regimen that included a platinum containing drug such as cispla...
What is the current status of trial NCT00365183?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2006-06. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00365183?
The interventions under investigation include: Motexafin gadolinium and pemetrexed (DRUG).
Who is sponsoring clinical trial NCT00365183?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00365183's enrollment target sits among peer trials
74 920th of 2000 higher than 1,077 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422731 · 74 participants · Early Phase 1
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
- NCT03804853 · 74 participants · NA
Rehabilitation Following Reverse Total Shoulder Arthroplasty
- NCT04065776 · 74 participants · NA
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
- NCT04771156 · 74 participants · Phase 4
Ketorolac in Palatoplasty
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia